---
title: "10x Genomics sees robust growth across platforms in Q4 2023"
date: "2025-02-13 04:53:53"
summary: "Earnings Call Insights: 10x Genomics (NASDAQ:TXG) Q4 2023 Management View CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with over $135 million in revenue for the year. The Xenium platform achieved over 250..."
categories:
  - "seekalpha"
lang:
  - "en"
translations:
  - "en"
tags:
  - "seekalpha"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Earnings Call Insights: 10x Genomics (NASDAQ:[TXG](https://seekingalpha.com/symbol/TXG "10x Genomics, Inc.")) Q4 2023

### Management View

* CEO Serge Saxonov highlighted strong growth across platforms, with total revenue for Q4 2023 reaching $184 million, an 18% increase year-over-year. Spatial products contributed significantly, with over $135 million in revenue for the year.
* The Xenium platform achieved over 250 instrument sales in its first year, exceeding internal expectations and reinforcing its position as a transformative product for in situ analysis.
* Visium HD, a key launch for the year, received positive customer feedback and demonstrated potential to drive translational research.
* GEM-X technology was introduced, reducing costs and increasing scalability for single cell research. This includes new assays with higher sensitivity and capture efficiency.
* CFO Adam Taich noted the company achieved positive free cash flow in Q4, with plans for disciplined spending and a continued focus on operational efficiency.

### Outlook

* Management expects full-year 2024 revenue to range between $670 million and $690 million, representing 8%-12% growth.
* Anticipates continued strong adoption of Xenium, with consumables ramping throughout the year.
* Plans to drive broader Visium HD adoption, supported by growing CytAssist placements.
* Aims to democratize single cell analysis through lower costs and expanded accessibility.

### Financial Results

* Consumables revenue totaled $140.3 million in Q4, up 7% year-over-year.
* Chromium consumables revenue was $118.1 million, while spatial consumables grew 95% to $22.2 million.
* Instrument revenue grew 72% year-over-year, driven by Xenium and CytAssist placements.
* Gross margin declined to 63%, impacted by higher Xenium instrument sales, which carry lower margins.
* Operating expenses increased due to R&D investments and technology acquisitions.

### Q&A

* Dan Brennan, Citi: Asked about growth drivers for 2024. CFO Taich highlighted robust demand for GEM-X and Visium HD, along with continued Xenium growth.
* Tejas Savant, Morgan Stanley: Questioned about Xenium adoption. CEO Saxonov noted strong initial placement numbers and confidence in long-term potential.
* Patrick Donnelly, Citi: Inquired about free cash flow targets. CFO Taich confirmed discipline in spending and focus on operational leverage.
* Kyle Mikson, Canaccord Genuity: Asked about biopharma traction. CEO Saxonov emphasized growing interest in single cell and spatial applications for drug development.

### Sentiment Analysis

* Management sentiment was optimistic, emphasizing strong product launches and adoption.
* Analysts expressed slight concern about gross margin trends and operational expenses but acknowledged strong topline growth.
* Overall, sentiment was slightly positive, reflecting confidence in new products and market opportunities.

### Quarter-over-Quarter Comparison

* Revenue grew 18% year-over-year and 9% sequentially.
* Spatial consumable growth accelerated, while gross margin declined due to higher Xenium instrument sales.
* Analysts' focus shifted from product adoption to margin management and operational efficiency.
* Compared to Q3, management demonstrated increased confidence in long-term growth driven by innovative products.

### Risks and Concerns

* Gross margin pressure due to lower-margin instrument sales.
* Potential delays in adoption for new products like Visium HD and GEM-X.
* Macroeconomic uncertainties could impact spending in academia and biopharma.

### Final Takeaway

10x Genomics delivered strong Q4 2023 results with substantial contributions from Xenium and Visium platforms. As the company enters 2024, its focus on expanding product adoption while managing margins and operational costs positions it well for sustained growth. Management's emphasis on democratizing single cell and spatial analysis through cost reductions and new capabilities underscores confidence in capturing long-term market opportunities.

[Read the full Earnings Call Transcript](https://seekingalpha.com/symbol/TXG/earnings/transcripts)

[seekalpha](https://seekingalpha.com/news/4407398-10x-genomics-sees-robust-growth-across-platforms-in-q4-2023)
